Compugen Reports Third Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Compugen Reports Third Quarter 2018 Results

Compugen (CGEN) Tops Q3 EPS by 10c, Revenues Beat

November 7, 2018 7:19 AM EST

Compugen (NASDAQ: CGEN) reported Q3 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.12 million versus the consensus estimate of $2.6 million.

"The last few months have been highly productive for Compugen, with strong execution marked by multiple key accomplishments. In September, we dosed the first patient in our Phase 1 COM701 study, which continues to progress as planned. Shortly thereafter, we signed a clinical collaboration agreement with Bristol-Myers Squibb, providing for the supply of Opdivo® for the combination arms of the trial, as well as establishing the... More